[Successful primary infliximab treatment of orofacial Crohn's disease without gastrointestinal manifestation].
Crohn's disease is a chronic inflammatory bowel disease that can involve the whole gastrointestinal tract. The orofacial manifestation of Crohn's disease, which is rare, can develop irrespective of intestinal involvement. These orofacial lesions are often misdiagnosed as simple oral ulcers. Corticosteroids are the mainstay of therapy for orofacial Crohn's disease. However, infliximab, the chimeric monoclonal antibody to tumor necrosis factor-a, is now considered as a primary treatment because of the disease's relatively high rate of steroid resistance. We present a case of deep oral ulcer and periorbital swelling in a 65-year-old woman. She was diagnosed with intestinal Crohn's disease 7 years ago, which was in remission after treatment with an immunosuppressive agent (azathioprine). The patient was given the diagnosed with orofacial Crohn's disease and successfully treated with infliximab.
Department of Gastroenterology, Cheonan Hospital, Soon Chun Hyang University College of Medicine, 31 Soonchunhyuang 6-gil, Dongnam-gu, Cheonan 330-721, Korea.
Bo Yong
BY
Jung
Suck-Ho
SH
Lee
Seung Kyu
SK
Chung
Chang Kyun
CK
Lee
Tae Hoon
TH
Lee
Il-Kwun
IK
Chung
Sun-Joo
SJ
Kim
Hyun-Deuk
HD
Cho
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005767:Gastrointestinal Diseases / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D015122:Mercaptopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D019226:Oral Ulcer / Q000175:diagnosis
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; C488629:azathiopurine; D000069285:Infliximab; D015122:Mercaptopurine